|
We are a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, and cancer.

|
| RECENT HIGHLIGHTS |
|
TTP054, a novel, orally active drug for glucose control, progresses towards completion of a phase 2 proof-of-concept clinical trial in type 2 diabetics
More Information
|
|
|
Novel, oral drug TTP488 shows promise for disease modification in Alzheimer's patients
More Information
|
|
|
|
|